Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a controversy involving China’s contract development and manufacturing organization (CDMO) Wuxi AppTec led the U.S. government to issue the BIOSECURE Act bill. To summarize, Wuxi allegedly shared confidential U.S. companies’ data with the Chinese government and the BIOSECURE Act aims to refrain U.S. biotech from contracting with Chinese CDMOs. However, if you look at the bigger picture, Chinese biotech is not only about CDMOs, and its role in the industry will definitely not end with the BIOSECURE Act’s enactment. Clarivate recently released a report – “A decade of innovation in China” – offering a comprehensive analysis of how the country’s biotech landscape has evolved over the past 10 years, driven by targeted policies and an increasingly global outlook.

Full commentary : The future of biotechnology firms in China.